Impact of Minor K103N HIV-1 Variants during Antiretroviral Therapy
Author Information
Author(s): Delobel Pierre, Saliou Adrien, Nicot Florence, Dubois Martine, Trancart Stéphanie, Tangre Philippe, Aboulker Jean-Pierre, Taburet Anne-Marie, Molina Jean-Michel, Massip Patrice, Marchou Bruno, Izopet Jacques, ANRS 106-Window Study Team
Primary Institution: Service des Maladies Infectieuses et Tropicales, Hôpital Purpan, Toulouse, France
Hypothesis
The study evaluates the importance of detecting minor populations of viruses resistant to NNRTIs during intermittent antiretroviral therapy.
Conclusion
Ultrasensitive methods can detect minor K103N HIV-1 variants that may predict treatment failure, but their presence does not always lead to virological escape.
Supporting Evidence
- Allele-specific real-time PCR detected K103N mutants in 15 of the 19 analyzable patients.
- The frequency of K103N mutants was <0.1% in 7 patients without further selection.
- The half-life of efavirenz was higher in patients with K103N emergence than in those without.
- Treatment failure occurred in 3 of the 8 patients with >0.1% K103N mutants.
Takeaway
This study looked at how tiny amounts of a specific HIV mutation can affect treatment. Sometimes, even if the mutation is there, it doesn't always mean the treatment will fail.
Methodology
A longitudinal study using allele-specific real-time PCR and ultra-deep pyrosequencing to detect K103N mutants in plasma samples from patients.
Potential Biases
Potential biases in patient selection and the retrospective nature of the analysis.
Limitations
The small sample size limits the generalizability of the findings.
Participant Demographics
21 HIV-1 infected patients (15 men, 6 women) with a median age of 38.6 years.
Statistical Information
P-Value
p<0.0001
Confidence Interval
[28.7–75.3]
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website